BridgeBio Pharma, Inc. (BBIO): Price and Financial Metrics

BridgeBio Pharma, Inc. (BBIO): $28.85

1.24 (+4.49%)

POWR Rating

Component Grades








Add BBIO to Watchlist
Sign Up

BBIO Price/Volume Stats

Current price $28.85 52-week high $44.32
Prev. close $27.61 52-week low $13.26
Day low $27.89 Volume 1,452,940
Day high $29.18 Avg. volume 1,707,580
50-day MA $27.88 Dividend yield N/A
200-day MA $30.48 Market Cap 5.40B

BBIO Stock Price Chart Interactive Chart >

BridgeBio Pharma, Inc. (BBIO) Company Bio

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

BBIO Latest News Stream

Event/Time News Detail
Loading, please wait...

BBIO Latest Social Stream

Loading social stream, please wait...

View Full BBIO Social Stream

Latest BBIO News From Around the Web

Below are the latest news stories about BRIDGEBIO PHARMA INC that investors may wish to consider to help them evaluate BBIO as an investment opportunity.

With BridgeBio Pharma's DNA, the Stock Could Continue to Soar Higher

BridgeBio Pharma has made a base pattern. The company finds, develops, and delivers breakthrough medicines for genetic diseases - a worthy mission. In this daily bar chart of BBIO, below, I can see that prices have climbed four-fold in the past twelve months.

Yahoo | December 28, 2023

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […]

Yahoo | December 26, 2023

3 Russell 2000 Stocks That Are About to Get Absolutely Crushed

The Russell 2000 has only begun closing its wide gap with other indices, but investors should be weary of these three stocks to sell.

Tyrik Torres on InvestorPlace | December 18, 2023

BridgeBio Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

- BridgeBio has dosed the first child in PROPEL 3, a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial evaluating the efficacy and safety of infigratinib in children with achondroplasia - The U.S. Food and Drug Administration (FDA) and European Union (EU) European Medicines Agency (EMA) shared positive feedback that the PROPEL 3 trial design would be acceptable as a registrational study to support a marketing application - Data from PROPEL 2, BridgeBio’s Phase 2 clinical trial o

Yahoo | December 13, 2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 05, 2023, the compensation committee of BridgeBio’s board of directors granted thirty new employees restricted stock units for an aggregate of 147,373 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock

Yahoo | December 8, 2023

Read More 'BBIO' Stories Here

BBIO Price Returns

1-mo 12.61%
3-mo -19.03%
6-mo -6.76%
1-year 110.28%
3-year N/A
5-year N/A
YTD -28.54%
2023 429.79%
2022 -54.32%
2021 -29.63%
2020 102.88%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!